TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10823399

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Nicotine spray
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Nicotine inhaler
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Continued use of NRT at week 15
Number of subjects: 504
Study: 2049554

Group type: EXPERIMENTAL
Intervention: MTX + CSA
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 40

Group type: COMPARATOR
Intervention: CSA
Number of subjects: 40
Study: 6404596

Group type: EXPERIMENTAL
Intervention: Low-dose combined oral contraceptive (ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injectable placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Copper T
Number of subjects: 0
Study: 30610027

Group type: EXPERIMENTAL
Intervention: Online, remotely delivered, therapist-supported exposure response prevention behavioural therapy for tics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online, remotely delivered, therapist-supported education about tics and co-occurring conditions
Number of subjects: 0
Study: 29911663

Group type: EXPERIMENTAL
Intervention: Educational program (talk, video projection, informative leaflets, narrative short stories, role-play activities)
Number of subjects: 970
Study: 27220840

Group type: EXPERIMENTAL
Intervention: Olmesartan/Amlodipine (OLM/AML) 20-40mg/5-10mg
Number of subjects: 88

Group type: COMPARATOR
Intervention: Perindopril/Amlodipine (PER/AML) 4-8mg/5-10mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Olmesartan/Amlodipine (OLM/AML)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Perindopril/Amlodipine (PER/AML)
Number of subjects: 88
Study: 24577854

Group type: EXPERIMENTAL
Intervention: Futsal (FUT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise (MOD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both FUT and MOD
Number of subjects: 20
Study: 22732225

Group type: EXPERIMENTAL
Intervention: Career academy attendance (full enrollment)
Number of subjects: 1306

Group type: EXPERIMENTAL
Intervention: Career academy attendance (partial enrollment)
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1306
Study: 20437287

Group type: EXPERIMENTAL
Intervention: Education session on drug-to-drug interactions
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no education session)
Number of subjects: 82
Study: 16889999

Group type: EXPERIMENTAL
Intervention: Hypnosis with analgesia suggestions
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hypnosis with relaxation suggestions
Number of subjects: 45

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 45
Study: 15767219

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day with telithromycin 800 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (single-dose) with telithromycin 800 mg/day
Number of subjects: 34
Study: 12504970

Group type: EXPERIMENTAL
Intervention: Active management with oral misoprostol (50 microg every 4 hours, max 5 doses)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Active management with oral misoprostol
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conservative management (induction with PGE(2) gel or oxytocin after 24 hours)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 61
Study: 9803051

Group type: EXPERIMENTAL
Intervention: Ayurvedic formulation (Misrakasneham)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional laxative tablet (Sofsena)
Number of subjects: 0
Study: 8613310

Group type: EXPERIMENTAL
Intervention: Furazolidone treatment
Number of subjects: 21
Study: 1956988

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6971716

Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 508

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 508
Study: 31535143

Group type: EXPERIMENTAL
Intervention: V160 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28652196

Group type: EXPERIMENTAL
Intervention: E.BMP‐2 with an HA carrier
Number of subjects: 93

Group type: COMPARATOR
Intervention: Autogenous iliac bone graft (AIBG)
Number of subjects: 93
Study: 26866549

Group type: EXPERIMENTAL
Intervention: Chlamydia testing intervention
Number of subjects: 13225
Study: 25003812

Group type: COMPARATOR
Intervention: Intramuscular clodronate 100mg/week (CLO) (N=36)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Yearly intravenous therapy with 5mg zoledronate (ZOL) (N=18)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (N=20)
Number of subjects: 74
Study: 22534658

Group type: EXPERIMENTAL
Intervention: Bupropion treatment
Number of subjects: 0
Study: 19639726

Group type: EXPERIMENTAL
Intervention: Olopatadine (5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17895350

Group type: EXPERIMENTAL
Intervention: Extension-oriented treatment approach (EOTA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Strengthening exercise program
Number of subjects: 48
Study: 15354104

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 325 mg aspirin
Number of subjects: 50

Group type: COMPARATOR
Intervention: 75 mg clopidogrel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison between aspirin and clopidogrel
Number of subjects: 50
Study: 12495795

Group type: EXPERIMENTAL
Intervention: Novel cognitive-behavioral treatment (CBT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Increased counseling (Control)
Number of subjects: 23
Study: 9718104

Group type: EXPERIMENTAL
Intervention: Intensive case management intervention
Number of subjects: 298
Study: 8007616

Group type: EXPERIMENTAL
Intervention: Subfascial lymphovenous anastomoses (LVA) operation combined with fenestration of the leg fascia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Epifascial LVA operation on the dorsal surface of the foot (Control group)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Subfascial lymphovenous anastomoses (LVA) operation
Number of subjects: 62
Study: 2260146

Group type: EXPERIMENTAL
Intervention: High-risk approach with drugs to reduce risk factors in individuals with high levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mass approach with lifestyle modifications for the general population
Number of subjects: 0
Study: 6779673

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion of 7.8 microgram . kg‐1 . mn‐1 (Group I)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No vasodilator drug (Group II)
Number of subjects: 6
Study: 31813763

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medicines review intervention (medicines education session, medicines optimisation session)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medicines review intervention
Number of subjects: 30
Study: 30507360

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome in normal weight patients (BMI 18.5-24.9 kg/m2)
Number of subjects: 3729

Group type: COMPARATOR
Intervention: Metabolic syndrome in overweight patients (BMI 25-29.9 kg/m2)
Number of subjects: 3729

Group type: COMPARATOR
Intervention: Metabolic syndrome in obese patients (BMI ≥30 kg/m2)
Number of subjects: 3729
Study: 28217871

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 25526271

Group type: EXPERIMENTAL
Intervention: Minipterional craniotomy (MPT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Classic pterional craniotomy (PT)
Number of subjects: 58
Study: 24106745

Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard protocol (Control)
Number of subjects: 102
Study: 21212059

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 752

Group type: COMPARATOR
Intervention: Control group (polyp-free individuals)
Number of subjects: 752
Study: 19186961

Group type: EXPERIMENTAL
Intervention: Bioactive ceramic filler (BCF)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 13
Study: 17893575

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 70
Study: 15065953

Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 134
Study: 11837466

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 grams elemental calcium daily from 20 weeks of gestation to delivery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No calcium supplementation (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 100
Study: 9497178

Group type: COMPARATOR
Intervention: 0 g psyllium seed husk (control)
Number of subjects: 286
Study: 7799829

Group type: EXPERIMENTAL
Intervention: E2 + NETA
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: E2V + LNG
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: E2V + MPA
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: E2 + DG
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 143
Study: 2529108

Group type: EXPERIMENTAL
Intervention: GR 38032F (0.15 mg/kg)
Number of subjects: 10
Study: 1068646

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis with oral nonabsorbed antibiotics and a nasal antibiotic ointment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Patient isolation and suppression of gut flora
Number of subjects: 36
Study: 30528592

Group type: EXPERIMENTAL
Intervention: Ebola vaccine trial participants
Number of subjects: 88

Group type: COMPARATOR
Intervention: Adjuvanted seasonal influenza vaccine trial participants
Number of subjects: 88
Study: 26621633

Group type: EXPERIMENTAL
Intervention: Protein-reduced infant formula with alpha-lactalbumin-enriched whey and free tryptophan and phenylalanine (IF)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Isocaloric standard formula without free amino acids (CF)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Breastfed infants (BF)
Number of subjects: 213
Study: 25408273

Group type: EXPERIMENTAL
Intervention: Double-balloon catheter
Number of subjects: 155

Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 155
Study: 23799922

Group type: EXPERIMENTAL
Intervention: LAN 90 mg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: LAN 120 mg
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 21406998

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 60-100 mg
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 502
Study: 19746429

Group type: EXPERIMENTAL
Intervention: 940 nm diode laser
Number of subjects: 24

Group type: COMPARATOR
Intervention: 532 nm diode laser
Number of subjects: 24
Study: 17089234

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 46
Study: 14734517

Group type: EXPERIMENTAL
Intervention: Selective adenosine A2A receptor agonist binodenoson (various doses)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 240
Study: 11150976

Group type: EXPERIMENTAL
Intervention: Patients with complete nerve lesions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 32
Study: 9212962

Group type: EXPERIMENTAL
Intervention: Integrated Myocardial Management (IMM)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Non-IMM
Number of subjects: 262
Study: 8021328

Group type: EXPERIMENTAL
Intervention: Clinical psychopharmacology curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teaching effectiveness and resident acceptance of the program
Number of subjects: 0
Study: 3482470

Group type: EXPERIMENTAL
Intervention: PGE2 in different vehicles for cervical ripening and labor induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31403574

Group type: EXPERIMENTAL
Intervention: Backward sled towing at 55% reduction of individual's maximal velocity (rVelmean)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Backward sled towing at 35% reduction of individual's maximal velocity (rVelmean)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Forward sled towing at 55% reduction of individual's maximal velocity (rVelmean)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Forward sled towing at 35% reduction of individual's maximal velocity (rVelmean)
Number of subjects: 18
Study: 28722766

Group type: EXPERIMENTAL
Intervention: mABQ method
Number of subjects: 6236

Group type: COMPARATOR
Intervention: GSQ method
Number of subjects: 6236

Group type: EXPERIMENTAL
Intervention: mABQ VFs
Number of subjects: 6236

Group type: EXPERIMENTAL
Intervention: Grade 1 mABQ VFs
Number of subjects: 6236
Study: 27457257

Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod 0.024%
Number of subjects: 25

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 25
Study: 25336668

Group type: EXPERIMENTAL
Intervention: CPVI + SVC-L
Number of subjects: 200

Group type: COMPARATOR
Intervention: CPVI
Number of subjects: 200
Study: 24423913

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway‐Supreme(TM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Common laryngeal mask airway
Number of subjects: 100
Study: 20839697

Group type: EXPERIMENTAL
Intervention: Cementless total hip replacement (THR)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cemented total hip replacement (THR)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Cementless tapered stem
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Cemented and cementless THR in patients younger than 65 years
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Cementless THR in male patients
Number of subjects: 250
Study: 18422606

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 16841676

Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SI) with chemotherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 45
Study: 14605733

Group type: EXPERIMENTAL
Intervention: Endoscopic, total extraperitoneal hernioplasty (TEP)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Lichtenstein hernioplasty
Number of subjects: 138
Study: 11036121

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil and prednisolone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone
Number of subjects: 42
Study: 8858271

Group type: EXPERIMENTAL
Intervention: 800 mg N-acetylcysteine (NAC) for 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 0
Study: 1620143

Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: L-DOPA methyl ester
Number of subjects: 6
Study: 3844158

Group type: EXPERIMENTAL
Intervention: High psychosocial care
Number of subjects: 26

Group type: COMPARATOR
Intervention: Low psychosocial care
Number of subjects: 26
Study: 31272494

Group type: EXPERIMENTAL
Intervention: Hypoglossal acupuncture
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 75

Group type: COMPARATOR
Intervention: Dietary recommendations
Number of subjects: 75
Study: 29354929

Group type: EXPERIMENTAL
Intervention: Five needles therapy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 210
Study: 25869479

Group type: EXPERIMENTAL
Intervention: Enteral glutamine (15 gr)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24489648

Group type: EXPERIMENTAL
Intervention: Mindfulness-related multi-component health promotion intervention (n = 129)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 257
Study: 22229478

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg p.o.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 20535920

Group type: EXPERIMENTAL
Intervention: Salviae injection and ligustrazine injection (S & L) in combination with conventional Western medical treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional Western medical treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Salviae injection and ligustrazine injection (S & L)
Number of subjects: 63
Study: 18007992

Group type: EXPERIMENTAL
Intervention: Global System for Mobile Communication (GSM) exposure
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Universal Mobile Telecommunications System (UMTS) exposure
Number of subjects: 176

Group type: COMPARATOR
Intervention: GSM signal during double-blind tests
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: UMTS signal during double-blind tests
Number of subjects: 176

Group type: COMPARATOR
Intervention: Physiological measures (blood volume pulse, heart rate, skin conductance)
Number of subjects: 176
Study: 16671427

Group type: EXPERIMENTAL
Intervention: Early surgical intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial conservative management
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVH absent
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVH present with hydrocephalus
Number of subjects: 0
Study: 12781936

Group type: EXPERIMENTAL
Intervention: Tailored decision aid (DA)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 224
Study: 11147227

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (BMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allogeneic BMT
Number of subjects: 0
Study: 8630464

Group type: EXPERIMENTAL
Intervention: Fast antipyrine metabolism in lung cancer patients and their first degree relatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate antipyrine metabolism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow antipyrine metabolism
Number of subjects: 0
Study: 1353720

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (250 micrograms/h for 96 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular Gold salts
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gold salts for 8 months with Somatostatin infusion at the fourth month
Number of subjects: 60
Study: 6362368

Group type: EXPERIMENTAL
Intervention: Procaine/haematoporphyrin (KH3)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 31453640

Group type: EXPERIMENTAL
Intervention: Connective Tissue Grafting (CTG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 15
Study: 30627845

Group type: EXPERIMENTAL
Intervention: 9 serial mud baths within 21 days in addition to a multimodal physical rehabilitative complex treatment
Number of subjects: 81

Group type: COMPARATOR
Intervention: Only physical rehabilitative treatment without mud baths
Number of subjects: 81
Study: 27811204

Group type: EXPERIMENTAL
Intervention: GDF‐15 (highest quartile)
Number of subjects: 14577
Study: 26391974

Group type: EXPERIMENTAL
Intervention: DAS181 (20mg) for 3 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DAS181 (20mg) for 10 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DAS181 (20mg) for 1 day
Number of subjects: 18
Study: 23689036

Group type: EXPERIMENTAL
Intervention: 1mM sucralose (SUCRA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 23
Study: 21988625

Group type: EXPERIMENTAL
Intervention: Repetitive testing (retest group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Repetitive studying (restudy group)
Number of subjects: 80
Study: 19853089

Group type: EXPERIMENTAL
Intervention: Dermabond skin glue
Number of subjects: 106

Group type: COMPARATOR
Intervention: Subcuticular sutures
Number of subjects: 106
Study: 17356110

Group type: EXPERIMENTAL
Intervention: Sildenafil therapy for 3 months
Number of subjects: 14
Study: 15639128

Group type: EXPERIMENTAL
Intervention: EEG power spectrum data during resting conditions
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Recording length increased from 40 to 400 s
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 4 s epochs of EEG power
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sample size increase
Number of subjects: 57
Study: 11716085

Group type: EXPERIMENTAL
Intervention: AH26
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kerr Pulp Canal Sealer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roths 801 (nonstaining)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 0
Study: 9164194

Group type: EXPERIMENTAL
Intervention: BEP (bleomycin, etoposide, and cisplatin)
Number of subjects: 598

Group type: COMPARATOR
Intervention: CEB (bleomycin, etoposide, and carboplatin)
Number of subjects: 598
Study: 7953038

Group type: EXPERIMENTAL
Intervention: Immediate community psychiatric nursing intervention
Number of subjects: 177

Group type: COMPARATOR
Intervention: Continuing GP care
Number of subjects: 177

Group type: COMPARATOR
Intervention: 12-week waiting-list for CPN intervention
Number of subjects: 177
Study: 2892458

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg a day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Betaxolol 20 mg a day
Number of subjects: 16